ArticleRadiation oncology journal2025
Postmastectomy radiation therapy for patients with pT1-2N1 breast cancer over 2 decades in Korea: Korean Radiation Oncology Group 14-21.
Article in Radiation oncology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study investigates patterns of postmastectomy radiation therapy (PMRT) use in patients with pT1-2N1 breast cancer treated with mastectomy in Korea over 2 decades. MATERIALS AND
methodsData from 700 patients treated at 16 institutions across three decades (1990, 2000, and 2010) were retrospectively reviewed.
resultsOverall, 10.0% of patients received PMRT, with utilization rates of 7.4%, 8.8%, and 11.1% in 1990, 2000, and 2010, respectively. The use of PMRT varied substantially among the hospitals (0%-87.5%). The two-dimensional radiotherapy was used in 1990, but the adoption of tangential beam three-dimensional conformal radiotherapy increased in subsequent decades. Axillary irradiation was performed in all patients in 1990 but was omitted in some cases starting in the 2000s (performed in 72.7% of cases in 2000, 84.1% in 2010). The inclusion of axillary levels, internal mammary nodes, and supraclavicular nodes decreased over time. The 10-year overall survival (OS) and recurrence-free survival (RFS) rates for all patients were 81.3% and 76.3%, respectively. Locoregional recurrence rates were significantly lower in the PMRT group (1.4%) compared to the no-PMRT group (8.1%, p=0.043). However, no significant differences were observed in 10-year OS, RFS, or distant metastasis-free survival rates between the two groups.
conclusionPMRT was performed in approximately 10% of patients with pT1-2N1 breast cancer after mastectomy, with minimal changes in utilization rates over two decades. The use and extent of regional nodal irradiation has declined over time. Further research is needed to reflect the latest patterns of practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.